19 research outputs found
Therapeutic Aspects of Dogs with Presumptive Diagnosis of Idiopathic Epilepsy
Background: Epilepsy is a chronic neurological condition characterised by recurrent epileptic seizures. Various antiepileptic drugs are used for the management of canine idiopathic epilepsy. Phenobarbital is the drug of choice for long-term treatment in dogs. Although it is well tolerated, phenobarbital can cause liver injury if administered alone or in combination with other drugs. Therefore, the main of this study was to identify dogs with presumptive diagnosis of idiopathic epilepsy and information about the antiepileptic drugs, the dose and frequency of administration, period of treatment, frequency of the seizure before and after start the treatment, complementary exams and adverse effects.Materials, Methods & Results: In this study were included 21 dogs with idiopathic epilepsy. All dogs were examined and having blood taken for blood count, biochemical tests (ALT, AST, AP, total protein, albumin, creatinine, urea, amylase, lipase, cholesterol and triglycerides), measurement of serum phenobarbital and/or potassium bromide and, some dogs, free T4 by dialysis and canine TSH. In this study, it was observed monotherapy (phenobarbital) in 76.19% (16/21), double therapy (phenobarbital and potassium bromide) in 19.05% (4/21) and triple therapy (phenobarbital, potassium bromide and gabapentin) in 4.76% (1/21) of dogs. The phenobarbital was used as monotherapy with dose between 1.4 and 12 mg kg-1 and the median of serum concentration was 26.41 μg kg-1. There was significant reduction in the frequency of the seizure after start the treatment. There was refractory to antiepileptic drugs in two dogs (9.5%). In blood analysis, there was increase serum activities of AP (23.81%) and ALT (14.20%), decrease total protein (42.29%), hypoalbuminemia (9.5%) and it was not increased AST activities. The main adverse effects were nodularliver damage and hypothyroidism.Discussion: In most cases of dogs with idiopathic epilepsy, monotherapy is preferred, because it tends to avoid complications that may arise from drug interactions and may also improve compliance by providing a simple treatment regimen. In this study, the phenobarbital controlled the seizures when used as monotherapy. It is considered success of an antiseizure drug when there is a reduction of seizure frequency by at least 50%, with minimal drug side effects. Approximately 20-30% of dogs with epilepsy do not have satisfactory seizure control or experience intolerable adverse effects with appropriate conventional medical treatment. In this study, there was refractory to antiepileptic drugs in 9.5%, one dog treated with phenobarbital and other with phenobarbital and potassium bromide. The long-term use of phenobarbital causes increase in liver enzymes, ALT and, mainly, ALP, these are attributed to enzymatic induction and to low degree of liver damage. ALT and AP increased the values and this does not necessarily indicate clinically significant liver damage or the need to stop therapy. The risk of liver toxicity appears to be greater with concentrations higher than 35 μg mL-1 or when multiple potentially hepatotoxic drugs are used. Other factors associated to the long-term use of anticonvulsant, such phenobarbital, potassium bromide or both, for the treatment of idiopathic epilepsy in dogs is acute pancreatitis and hypothyroidism. In this study, it was not observed acute pancreatitis, but there were two dogs with hypothyroidism. The long-term use of phenobarbital did not cause significant side effects, even with changes in the biochemical tests
Characterization of advanced glycation end products and their receptor (RAGE) in an animal model of myocardial infarction
Circulating advanced glycation end products (AGE) and their receptor, RAGE, are increased after a myocardial infarction (MI) episode and seem to be associated with worse prognosis in patients. Despite the increasing importance of these molecules in the course of cardiac diseases, they have never been characterized in an animal model of MI. Thus, the aim of this study was to characterize AGE formation and RAGE expression in plasma and cardiac tissue during cardiac remodeling after MI in rats. Adult male Wistar rats were randomized to receive sham surgery (n = 15) or MI induction (n = 14) by left anterior descending coronary artery ligation. The MI group was stratified into two subgroups based on postoperative left ventricular ejection fraction: low (MIlowEF) and intermediate (MIintermEF). Echocardiography findings and plasma levels of AGEs, protein carbonyl, and free amines were assessed at baseline and 2, 30, and 120 days postoperatively. At the end of follow-up, the heart was harvested for AGE and RAGE evaluation. No differences were observed in AGE formation in plasma, except for a decrease in absorbance in MIlowEF at the end of follow-up. A decrease in yellowish-brown AGEs in heart homogenate was found, which was confirmed by immunodetection of N-ε-carboxymethyl-lysine. No differences could be seen in plasma RAGE levels among the groups, despite an increase in MI groups over the time. However, MI animals presented an increase of 50% in heart RAGE at the end of the follow-up. Despite the inflammatory and oxidative profile of experimental MI in rats, there was no increase in plasma AGE or RAGE levels. However, AGE levels in cardiac tissue declined. Thus, we suggest that the rat MI model should be employed with caution when studying the AGERAGE signaling axis or anti-AGE drugs for not reflecting previous clinical findings
Therapeutic Aspects of Dogs with Presumptive Diagnosis of Idiopathic Epilepsy
Background: Epilepsy is a chronic neurological condition characterised by recurrent epileptic seizures. Various antiepileptic drugs are used for the management of canine idiopathic epilepsy. Phenobarbital is the drug of choice for long-term treatment in dogs. Although it is well tolerated, phenobarbital can cause liver injury if administered alone or in combination with other drugs. Therefore, the main of this study was to identify dogs with presumptive diagnosis of idiopathic epilepsy and information about the antiepileptic drugs, the dose and frequency of administration, period of treatment, frequency of the seizure before and after start the treatment, complementary exams and adverse effects.Materials, Methods & Results: In this study were included 21 dogs with idiopathic epilepsy. All dogs were examined and having blood taken for blood count, biochemical tests (ALT, AST, AP, total protein, albumin, creatinine, urea, amylase, lipase, cholesterol and triglycerides), measurement of serum phenobarbital and/or potassium bromide and, some dogs, free T4 by dialysis and canine TSH. In this study, it was observed monotherapy (phenobarbital) in 76.19% (16/21), double therapy (phenobarbital and potassium bromide) in 19.05% (4/21) and triple therapy (phenobarbital, potassium bromide and gabapentin) in 4.76% (1/21) of dogs. The phenobarbital was used as monotherapy with dose between 1.4 and 12 mg kg-1 and the median of serum concentration was 26.41 μg kg-1. There was significant reduction in the frequency of the seizure after start the treatment. There was refractory to antiepileptic drugs in two dogs (9.5%). In blood analysis, there was increase serum activities of AP (23.81%) and ALT (14.20%), decrease total protein (42.29%), hypoalbuminemia (9.5%) and it was not increased AST activities. The main adverse effects were nodularliver damage and hypothyroidism.Discussion: In most cases of dogs with idiopathic epilepsy, monotherapy is preferred, because it tends to avoid complications that may arise from drug interactions and may also improve compliance by providing a simple treatment regimen. In this study, the phenobarbital controlled the seizures when used as monotherapy. It is considered success of an antiseizure drug when there is a reduction of seizure frequency by at least 50%, with minimal drug side effects. Approximately 20-30% of dogs with epilepsy do not have satisfactory seizure control or experience intolerable adverse effects with appropriate conventional medical treatment. In this study, there was refractory to antiepileptic drugs in 9.5%, one dog treated with phenobarbital and other with phenobarbital and potassium bromide. The long-term use of phenobarbital causes increase in liver enzymes, ALT and, mainly, ALP, these are attributed to enzymatic induction and to low degree of liver damage. ALT and AP increased the values and this does not necessarily indicate clinically significant liver damage or the need to stop therapy. The risk of liver toxicity appears to be greater with concentrations higher than 35 μg mL-1 or when multiple potentially hepatotoxic drugs are used. Other factors associated to the long-term use of anticonvulsant, such phenobarbital, potassium bromide or both, for the treatment of idiopathic epilepsy in dogs is acute pancreatitis and hypothyroidism. In this study, it was not observed acute pancreatitis, but there were two dogs with hypothyroidism. The long-term use of phenobarbital did not cause significant side effects, even with changes in the biochemical tests
Therapeutic Aspects of Dogs with Presumptive Diagnosis of Idiopathic Epilepsy
Background: Epilepsy is a chronic neurological condition characterised by recurrent epileptic seizures. Various antiepileptic drugs are used for the management of canine idiopathic epilepsy. Phenobarbital is the drug of choice for long-term treatment in dogs. Although it is well tolerated, phenobarbital can cause liver injury if administered alone or in combination with other drugs. Therefore, the main of this study was to identify dogs with presumptive diagnosis of idiopathic epilepsy and information about the antiepileptic drugs, the dose and frequency of administration, period of treatment, frequency of the seizure before and after start the treatment, complementary exams and adverse effects.Materials, Methods & Results: In this study were included 21 dogs with idiopathic epilepsy. All dogs were examined and having blood taken for blood count, biochemical tests (ALT, AST, AP, total protein, albumin, creatinine, urea, amylase, lipase, cholesterol and triglycerides), measurement of serum phenobarbital and/or potassium bromide and, some dogs, free T4 by dialysis and canine TSH. In this study, it was observed monotherapy (phenobarbital) in 76.19% (16/21), double therapy (phenobarbital and potassium bromide) in 19.05% (4/21) and triple therapy (phenobarbital, potassium bromide and gabapentin) in 4.76% (1/21) of dogs. The phenobarbital was used as monotherapy with dose between 1.4 and 12 mg kg-1 and the median of serum concentration was 26.41 μg kg-1. There was significant reduction in the frequency of the seizure after start the treatment. There was refractory to antiepileptic drugs in two dogs (9.5%). In blood analysis, there was increase serum activities of AP (23.81%) and ALT (14.20%), decrease total protein (42.29%), hypoalbuminemia (9.5%) and it was not increased AST activities. The main adverse effects were nodularliver damage and hypothyroidism.Discussion: In most cases of dogs with idiopathic epilepsy, monotherapy is preferred, because it tends to avoid complications that may arise from drug interactions and may also improve compliance by providing a simple treatment regimen. In this study, the phenobarbital controlled the seizures when used as monotherapy. It is considered success of an antiseizure drug when there is a reduction of seizure frequency by at least 50%, with minimal drug side effects. Approximately 20-30% of dogs with epilepsy do not have satisfactory seizure control or experience intolerable adverse effects with appropriate conventional medical treatment. In this study, there was refractory to antiepileptic drugs in 9.5%, one dog treated with phenobarbital and other with phenobarbital and potassium bromide. The long-term use of phenobarbital causes increase in liver enzymes, ALT and, mainly, ALP, these are attributed to enzymatic induction and to low degree of liver damage. ALT and AP increased the values and this does not necessarily indicate clinically significant liver damage or the need to stop therapy. The risk of liver toxicity appears to be greater with concentrations higher than 35 μg mL-1 or when multiple potentially hepatotoxic drugs are used. Other factors associated to the long-term use of anticonvulsant, such phenobarbital, potassium bromide or both, for the treatment of idiopathic epilepsy in dogs is acute pancreatitis and hypothyroidism. In this study, it was not observed acute pancreatitis, but there were two dogs with hypothyroidism. The long-term use of phenobarbital did not cause significant side effects, even with changes in the biochemical tests
Prednisona e meloxicam no tratamento de ratos submetidos ao trauma agudo da medula espinhal
O objetivo deste estudo foi investigar o efeito da prednisona e do meloxicam na terapia de ratos submetidos ao modelo experimental de trauma agudo da medula espinhal, induzida pelo cateter de Fogarty 2Fr, mediante a avaliação dos parâmetros de estresse oxidativo, dos testes neurológicos e do exame histopatológico da medula espinhal. Foram utilizados 90 ratos Wistar, distribuídos em seis grupos, denominados controle salina ou GCS (n=15), controle prednisona ou GCP (n=15), controle meloxicam ou GCM (n=15), trauma mais salina ou GTS (n=15), trauma mais prednisona ou GTP (n=15) e trauma mais meloxicam GTM (n=15). Cada grupo foi redistribuído em três subgrupos de igual número, de acordo com o tempo de tratamento no pós-operatório de 24h, 72h e sete dias. Todos os grupos foram submetidos à laminectomia e, nos grupos GTS, GTM e GTP, após a exposição da medula espinhal, foi realizado o trauma medular compressivo, utilizando o cateter de Fogarty 2Fr. Os grupos GCS e GTS foram tratados com solução salina, os GSM e GTM receberam meloxicam e os GSP e GTP prednisona, sendo administrados pela via intraperitoneal. Em todos os ratos, foram avaliados os parâmetros de estresse oxidativo, testes neurológicos e exame histopatológico da medula espinhal. Os animais dos grupos GTS, GTM e GTP, nos diferentes tempos (24h, 72h e sete dias), tiveram pontuação zero na escala de Basso, Beattie e Bresnahan (BBB); no plano inclinado, permaneceram com pontuação três e perderam a percepção da dor profunda. Os grupos GTM e GTP apresentaram menor atividade da catalase e de níveis de TBARS, quando comparado ao grupo GTS. Foi constatada degeneração Walleriana e necrose da substância cinzenta de intensidades variáveis, não apresentando diferença entre os grupos submetidos ao trauma. O meloxicam e a prednisona apresentam possível efeito antioxidante, mas não impedem a necrose e a degeneração Walleriana da medula espinhal de ratos